Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D P Lane

Showing results (81-90 of 259) with videos related to

Pageof 26
Sort By:
The Journal of Biological Chemistry|February 16, 1996
Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC Cell Transformation GroupS Hansen, T R Hupp, D P Lane
Biochemical and Biophysical Research Communications|June 29, 1983
Monoclonal antibodies to leucine enkephalinC A Jones, D P Lane, J Hughes
Neoplasma|January 1, 1991
Asymmetric PCR-based strategy for genetic analysis of the p53 tumor suppressor gene in cell lines and tumor tissuesJ Bártek, R Iggo, B Vojtĕsek, et al.
The Journal of Pathology|May 26, 1999
New approaches to cancer therapiesR Fåhraeus, P Fischer, E Krausz, et al.
Oncogene|October 1, 1994
Xenopus p53 is biochemically similar to the human tumour suppressor protein p53 and is induced upon DNA damage in somatic cellsL S Cox, C A Midgley, D P Lane
Journal of Virology|August 1, 1986
Monoclonal antibody analysis of p53 expression in normal and transformed cellsJ W Yewdell, J V Gannon, D P Lane
Yeast (Chichester, England)|March 1, 1986
Identification of the RNA2 protein of Saccharomyces cerevisiaeM G Lee, D P Lane, J D Beggs
Experimental Cell Research|October 13, 2001
Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53D P Xirodimas, C W Stephen, D P Lane
The Biochemical Journal|November 4, 2000
Strategies for manipulating the p53 pathway in the treatment of human cancerT R Hupp, D P Lane, K L Ball
Journal of Clinical Pathology|February 1, 1993
p53 expression in dyskeratosis congenita: a marker for oral premalignancy?G R Ogden, D P Lane, D M Chisholm
Pageof 26

Showing results (81-90 of 259) with videos related to

Sort By:
Pageof 26
The Journal of Biological Chemistry|February 16, 1996
Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC Cell Transformation GroupS Hansen, T R Hupp, D P Lane
Biochemical and Biophysical Research Communications|June 29, 1983
Monoclonal antibodies to leucine enkephalinC A Jones, D P Lane, J Hughes
Neoplasma|January 1, 1991
Asymmetric PCR-based strategy for genetic analysis of the p53 tumor suppressor gene in cell lines and tumor tissuesJ Bártek, R Iggo, B Vojtĕsek, et al.
The Journal of Pathology|May 26, 1999
New approaches to cancer therapiesR Fåhraeus, P Fischer, E Krausz, et al.
Oncogene|October 1, 1994
Xenopus p53 is biochemically similar to the human tumour suppressor protein p53 and is induced upon DNA damage in somatic cellsL S Cox, C A Midgley, D P Lane
Journal of Virology|August 1, 1986
Monoclonal antibody analysis of p53 expression in normal and transformed cellsJ W Yewdell, J V Gannon, D P Lane
Yeast (Chichester, England)|March 1, 1986
Identification of the RNA2 protein of Saccharomyces cerevisiaeM G Lee, D P Lane, J D Beggs
Experimental Cell Research|October 13, 2001
Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53D P Xirodimas, C W Stephen, D P Lane
The Biochemical Journal|November 4, 2000
Strategies for manipulating the p53 pathway in the treatment of human cancerT R Hupp, D P Lane, K L Ball
Journal of Clinical Pathology|February 1, 1993
p53 expression in dyskeratosis congenita: a marker for oral premalignancy?G R Ogden, D P Lane, D M Chisholm
Pageof 26